Compare Crispr Therapeutics AG (CRSP) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Payoneer Global Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Payoneer Global Inc trades at $7.14 (market cap $2.43B). The key difference: Crispr Therapeutics AG is far larger — about 2× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Payoneer Global Inc for 61 Days on average.
| CRSP | PAYO | |
|---|---|---|
Market Cap | $4.88B | $2.43B |
Volume | 2,861,747 | 1,342,701 |
Sector | Health | Technology |
52-Week High | $74.92 | $7.18 |
52-Week Low | $44.34 | $4.27 |
Typical Hold Time | 77 Days | 61 Days |
Enterprise Value | $3.30B | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Payoneer Global (PAYO) trades at $7.16 with a bullish technical signal supported by moving averages, though oscillators show neutral momentum. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but revenue grew 10% excluding interest. Recent news highlights the renewal of Payoneer's partnership with Etsy through 2029 and an agreement to be acquired by Nuvei, announced on June 15, 2026.
The outlook is mixed: analyst consensus is 60% buy with no sell ratings, but earnings misses and a high P/E of 51.18 pose valuation concerns. Key risks include integration challenges from the Nuvei acquisition and competitive pressures in fintech. Upside potential hinges on execution of B2B growth and expansion in India.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
